Member Info for jam2morrow

Agree about the cost @neon , there should still be some market for this tech tho'. Von jacko did say about pinpointing lung cancer before treatments. Otherwise its too vague for me.

Pulmonary embolism is a big market but that has never been mentioned by the company . It may be that cyclopharm have clearance for gas exchange and thats why they can target market PE.

They need sales or some sort of commercial tie up. Amati still seem to still be on board and advising on financial options so thats some kind of positive. I'm not holding my breath tho, even for a single 10 second dose

Too depressing for me to look in here a lot, but this was a good find @neon - cyclopharms technegas gets fda approval.

I've never seen it mentioned before but obviously I should have known about it if my research had been extensive enough.

They are using radioactive tracer from technetium 99m. The disadvantage is the low dose radioactivity but that hasn't stopped cyclopharm tech being already used in 60 countries and producing revenue of 30m aus dollar last year.

One very interesting takeaway for me, on doing a bit of reading, is that cyclopharm's tech is being used primarily as a diagnostic tool for pulmonary embolism. Now, I have asked POLX at investor presentation back in February? if our tech could pick up pulmonary embolism - there was no reply. I can't see how the cyclopharm tech gives better, or more expansive imaging, beyond the chest cavity. Any thoughts anyone ?

Still no sales , and I can't believe that pharma co's developing asthma drugs don't want to buy our product - how are they evaluating lung function in patients trialling new drugs ?

The market seems to be predict failure here. I was quite impressed with new CEO's presentation but he needs sales....clock is ticking

Yes, @Laconic, that needs to be re-phrased - the hospitals need to be sure that their initial outlay and ongoing costs are going to be recouped; and more so than their current practices. The picture painted here has always been good, thats why we're here; but nobody's buying, and that needs to change pronto.

He did go into the haematology side here which was useful because it leads to far more diagnostic possibilities but they need to be able to sell some of these on the gas capability alone; the timelines and the finances are too tight to wait for that extra approval

I thought Von Jacko came across well. Was a bit vague on how this tech will save hospitals money, but at least kind of answered it. Hospital admins need to know that they can do x y and z with this tech and what money it will save them.

get orders, hope sp rises, then raise......he will have his own targets in mind

@Doppo: the person who has to deliver the good news will be speaking tomorrow at 10am on the investor meet. He needs to address the share price collapse and tell us why no-one is buying the product.

Price is so low now that If it goes to zero I won't lose too much more.

I'm not going to beat myself up about it, but i should have had some kind of stop loss in the 30's or 40's. On paper this is my biggest loss in 25 years.

M cap now is just under £20mil......what do they have in cash ? £10 Mil ?......so the market is valuing the product at about £10mil......doesn't look good

'' if you can make a heap of all your winnings

and risk it on one turn of pitch and toss,

and lose, and start again at your beginnings,

and never breath a word about your loss''..........If - Kipling

Https://venturebeat.com/ai/vida-diagnostics-raises-11-million-to-diagnose-lung-diseases-with-ai/

quite a good summary in above link where VIDA raised money in '22.

Company seems to have evolved from existing healthcare facilities in Iowa; more here:

https://www.thisisiowa.com/story/26/the-right-treatment-at-the-right-time/

Private company which makes it difficult to value, but maybe other posters can come up with something ? must be some way of finding revenues etc.

Basically they seem to be offering what POLX does ( and I should have known this if i had done my DD properly before investing here). They are using tMPR visualisation, so, topographic multi planar representation. Taking MRI scans CT scans and building up pictures using AI .

They seem to have built up a good customer base and, importantly, drug manufacturers are using their tech in their trials.

Obviously lots of questions; POLX must have known about VIDA but , I think, convinced many investors that no-one else was already operating in their space.

How many companies/ organisations will not buy POLX tech because they already have VIDA's ?

Were POLX hoping that their tech would surpass VIDA ? The collaboration RNS suggests recognition that this will not happen.

Lots to think about. I wonder how much of this will be addressed in upcoming presentation ?

If this collaboration is down to von Jacko then its a positive. A lot of techno gobbledigook in that RNS but worth researching VIDA over the w/e to get better understanding. The anticipated sales to the research hospitals don't appear to be happening and they were the easy targets.....at some point I will have to try to average down on this, either that or write the company off and look for a better investment

100m !! @ shpunken...... i would think £40m is very optimistic.....the company has no value if nobody wants the product.

I am surprised that we cannot make sales to pulmonary drug trial companies, this would seem to be a very good fit for a company trialling an asthma drug, for example. For treating disease, accurate pictures of gas movement thru the lungs would appear not to be critical to treatment process - hence no sales.

Any pulmonologists on the chatboard ? why would this tech be useful to you ?

Also noted that Angle (AGL) have released a good rns today and are up about the same amount we are down.....AGL, a company that has been compared to polx before

Nukem got the amati shares ?

not bought on open market by looks of sp

people buying the product will mean people buying the shares......8mths post approval and we have sweet fda....which is why we are where we are

What are u seeing @unhooked ?

I know what investors are not seeing - any sales

No sales means no company; if it continues like this

Fair comment Dulyred; and probably why we've had the CEO change. For hospitals to buy it, then there needs to be evidence that it can save them money; accurate graphics of lung function is very nice but if the treatment is still the same as before then no financial incentive to buy.

The case for drug development companies is stronger but obviously far smaller potential customer base. This and MRI makers themselves may drive some sales.

I think your window of 'a few more months' is also a fair timeframe for the new guy to vindicate his appointment

Interview with Dr Paul Jourdan that I missed when it was put up on you tube 6 days ago. Polx NOT discussed, at least, not on camera......draw your own conclusions. Some discussion of medical stocks and take up of new product by the health care industry was pertinent to this stock tho'.

Hopefully found a bottom at 20p, but raising at this level is going to hurt. Need sales, and soon.

also from companies website, as of March 2023 : about 40% belonging to ii's + bracco + nukem. Numbers haven't changed for a while.
https://www.polarean-ir.com/content/investors/shareholder-information

POLX need to be promoting exactly what their lung imaging can pick up. I don't think that it would be a better option than the CT scans talked about in referenced article because they are talking about picking up early stage cancer signs.
I don't think it would be a better option, but I don't know so. If POLX tech can be used to detect early lung cancer tumour growth then they need to be shouting it from the hospital roof tops !

lithium stocks in general have been on recovery run: ALL. BHL, SAV, ATM.....EMH to a lesser extent (whats going on there ? I ought to take more notice as its our geographical neighbour) but they have all fallen a long way in last year or so, like ZNWD

good news/ bad news ......depends which way u want to spin it. Does it look like the sales roll out is not rolling out ?......even after all that extra prep time ? Maybe this guy is supposed to kick start it a bit ; but he has been non-exec, so how much input did he have in that capacity? Probably needs that $300 per hour to motivate himself, luckily he is chairman of the remuneration committee so must know what he is worth :(
How's that cash burn going guys ?
Doesn't read well to me, but proof will be in the pudding if they start selling stuff.

Thanks guys. Would like to see VOX get Paul Jourdan on again, he was one of their regulars

Sharp move up in Saietta (SED) sp this morning after long decline.......the relevance here ? .....Saietta is(was ?) one of the larger holdings in Amati's VCT fund; but checking this morning it does not seem to be in top 10 holdings any more; also, Polarean now (as of 28th Feb) represents 3.3% of the fund and I'm pretty sure that this has come down from 5% a few months back. No change in %age holding on Polarean website by Amati but that may not be an up to date figure.

yes @jay, and i see that companies researching new drugs to treat, for example, asthma, will benefit greatly from this tech.....here is a picture of lung function before taking drug....here is a picture of lung function after taking drug. The market for research applications is obviously much smaller than for disease treatment. That is my question for POLX (that they haven't answered yet) : How does this tech help decide drug and treatment process in pulmonary hospitals and how does it save them money ?
That's my thoughts at the moment, that the sales market is limited to research hospitals and companies producing new drugs for pulmonary disease. Bracco and Amati surely must see a bigger market potential than just for research, but I am struggling to see it

Kromek still trading tho' and seem to be generating orders ? if its KMK you mean ?......maybe thats what will happen here, getting just enough business to survive.
All seems too vague here; for instance, asthma is a massive global problem and hence a massive market; POLX tech gives best images of lung function but how do those images change treatment process and how do they improve outcomes ? The company has still not answered the questions from the presentation a month ago